Drug Development

Breaking News | Drug Development | Promotions & Moves

Evox Therapeutics Taps Dr. Per Lundin as CEO

Lundin has 15+ years’ experience founding, leading and advising biotech companies, including co-founding Evox in 2016.

04.29.24

Bio News | Breaking News | Drug Development | Promotions & Moves

Alentis Names Dr. Alberto Toso as Chief Scientific Officer

Toso has more than 10 years of drug development experience in small and large molecules for immune oncology (IO) and targeted therapies.

04.29.24

Breaking News | Collaborations & Alliances | Drug Development

BMS, Repertoire Immune Medicines Enter Strategic Autoimmune Vax Pact

Leverages Repertoire's DECODE platform to develop T cell targeted immune medicines.

04.29.24

Breaking News | Drug Development

Regeneron & Mammoth Partner on CRISPR Therapies

Aim to create disease-modifying medicines that can be delivered to tissues beyond the liver, to which most gene editing treatments are currently limited.

04.25.24

Breaking News | Drug Development | Promotions & Moves

Ascend Taps Scott Law as COO

Law brings more than 30 years of global pharmaceutical experience.

04.25.24

Breaking News | Drug Development | Industry News

Kühne Holding AG Agrees to Acquire Aenova Group

Enlarges its investment portfolio to include healthcare and pharmaceutical assets.

04.24.24

Breaking News | Collaborations & Alliances | Drug Development

BigHat Biosciences Partners with Janssen Biotech to Guide Antibody Discovery & Design

Collaboration will combine the drug discovery, clinical development and data science expertise from Johnson & Johnson with BigHat’s AI/ML platform.

04.24.24

Breaking News | Collaborations & Alliances | Drug Development

Tetra Pharm Technologies & Glysious Partner to Develop Transdermal Combination Drugs

Aim to revolutionize transdermal release of ‘difficult-to-formulate’ compounds targeting the endocannabinoid system.

04.24.24

Breaking News | Drug Development | Trials & Filings

Sanofi’s Rilzabrutinib Meets Primary Endpoint in ITP

Demonstrates significantly higher proportion of patients receiving rilzabrutinib achieved primary endpoint of durable platelet response versus placebo.

04.23.24

Breaking News | Collaborations & Alliances | Drug Development

Tharimmune Announces Option for Novel HER2/HER3 Cancer Therapies

Obtains rights from Washington University to develop and incorporate human HER2 directed antibodies.

04.23.24

Breaking News | Clinical Trials | Drug Development | Promotions & Moves

Calluna Names Senior Vice President of Clinical Operations & Pharmacovigilance

Margrethe Sørgaard offers 25 years’ experience in leading positions in clinical development and operation, medical affairs and drug safety/pharmacovigilance.

04.23.24

Breaking News | Drug Development | Industry News

Lexeo Enters License Agreement for Friedreich Ataxia Treatment

Aims to expedite development of investigational gene therapy candidate LX2006 for the treatment of FA cardiomyopathy.

04.22.24

Breaking News | Collaborations & Alliances | Drug Delivery | Drug Development

BioArctic, Eisai Ink Research Agreement for BAN2802 in AD

To evaluate potential new treatment combining BioArctic's BrainTransporter technology with an undisclosed Alzheimer drug candidate.

04.22.24

Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery

Ipsen and Skyhawk Therapeutics Collaborate on RNA Targeting Research

Aim to discover and develop small molecules for the treatment of rare neurological diseases.

04.22.24

Breaking News | Drug Development | Promotions & Moves

SystImmune Names New CEO

Taps former Bristol Myers Squibb exec with 20 years’ experience in the biopharmaceutical industry.

04.22.24

Breaking News | Drug Development | Trials & Filings

Genentech's Alecensa Approved in Early-Stage NSCLC

Phase III ALINA study demonstrates Alecensa reduced the risk of disease recurrence or death by 76%.

04.19.24

Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Drug Development | Industry News

ExoXpert, Neucore Bio to Evaluate Advanced Exosome Loading

Aims to enable greater clarity on maximizing the therapeutic effect of Neucore’s FiXE platform as it advances clinical development.

04.18.24

Breaking News | Collaborations & Alliances | Drug Development | Drug Discovery

Evotec and Variant Bio Partner to Discover & Develop Treatments for Fibrosis

The partnership leverages Variant Bio’s genomic discovery capabilities and VB-Inference platform as well as Evotec’s expertise in antifibrotic drug discovery.

04.18.24

Breaking News | Drug Development | Industry News | Information Technology